SSGJ-705

DRUG4 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shenyang Sunshine Pharmaceutical Co., LTD.

Conditions

Locally Advanced (Unresectable) or Metastatic Solid TumorsLocally Advanced, Recurrent or Metastatic MalignanciesReceptor, ErbB-2

Phase 1

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Receptor, ErbB-2

Start: 2021-12-01End: 2024-06-01Target: 162Updated: 2021-12-06

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

RecruitingNCT06390774

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Locally Advanced, Recurrent or Metastatic Malignancies

Start: 2024-05-30End: 2027-02-28Target: 180Updated: 2024-10-18

Phase 2

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

RecruitingNCT07022002

Shenyang Sunshine Pharmaceutical Co., LTD.Locally Advanced, Recurrent or Metastatic Malignancies

Start: 2025-07-30End: 2027-12-12Target: 340Updated: 2025-08-03

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

RecruitingNCT07646626

Shenyang Sunshine Pharmaceutical Co., LTD.Locally Advanced (Unresectable) or Metastatic Solid Tumors

Start: 2026-07-17End: 2028-10-31Target: 150Updated: 2026-07-28